Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603035054> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2603035054 abstract "710 Background: CAPOX and FOLFOX are used interchangeably in the adjuvant treatment of colon cancer despite the lack of comparative phase III trials.We aimed to compare toxicities, relative dose intensity (RDI), disease free (DFS) and overall survival (OS) of these regimens in the real world. Methods: We identified consecutively treated patients (pts) with stage III colon cancer at two centers who received either CAPOX or mFOLFOX6 when either option was accessible to pts. RDI was defined as total dose received divided by the total intended dose if all cycles had been delivered. Dose limiting toxicities (DLTs) were toxicities that resulted in a dose reduction of an agent. Survival was compared with the log-rank test and Cox models that adjusted for age, gender, ECOG, T-stage, and N-stage. Results: Of 394 pts, 61.7% received FOLFOX. Age, gender, ECOG, T-stage, N-stage, and time between surgery and start of therapy did not differ between groups. However, RDI and toxicity profiles differed between treatment groups (see Table). With a median follow up of 45 months, there was no difference in OS (HR 0.73, 95%CI 0.45-1.22; P= 0.24); however, CAPOX was associated with a more favorable DFS (HR 0.61, 95% CI 0.40-0.93; P= 0.022). In multivariate analysis, treatment with CAPOX showed trends towards improved OS (HR 0.61, 95% CI 0.34-1.07; P= 0.086). A significant association with improved DFS (HR 0.53, 95% CI 0.33-0.87; P= 0.012) persisted. Exploratory analysis comparing outcomes stratified by the presence of any DLT, neutropenia, thrombocytopenia, and neuropathy failed to show an association with either OS or DFS. (See table.) Conclusions: Our findings suggest that the use of adjuvant CAPOX is associated with an improved DFS despite greater toxicity and lower RDI. Patient selection, the higher starting dose of oxaliplatin in CAPOX, or the metronomic nature of capecitabine may be contributing to improved efficacy of CAPOX. [Table: see text]" @default.
- W2603035054 created "2017-04-07" @default.
- W2603035054 creator A5008288310 @default.
- W2603035054 creator A5014350537 @default.
- W2603035054 creator A5026112445 @default.
- W2603035054 creator A5039850848 @default.
- W2603035054 creator A5052444047 @default.
- W2603035054 creator A5053138163 @default.
- W2603035054 creator A5067235730 @default.
- W2603035054 creator A5070331492 @default.
- W2603035054 creator A5078936080 @default.
- W2603035054 creator A5080445374 @default.
- W2603035054 date "2017-02-01" @default.
- W2603035054 modified "2023-09-28" @default.
- W2603035054 title "Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer." @default.
- W2603035054 doi "https://doi.org/10.1200/jco.2017.35.4_suppl.710" @default.
- W2603035054 hasPublicationYear "2017" @default.
- W2603035054 type Work @default.
- W2603035054 sameAs 2603035054 @default.
- W2603035054 citedByCount "0" @default.
- W2603035054 crossrefType "journal-article" @default.
- W2603035054 hasAuthorship W2603035054A5008288310 @default.
- W2603035054 hasAuthorship W2603035054A5014350537 @default.
- W2603035054 hasAuthorship W2603035054A5026112445 @default.
- W2603035054 hasAuthorship W2603035054A5039850848 @default.
- W2603035054 hasAuthorship W2603035054A5052444047 @default.
- W2603035054 hasAuthorship W2603035054A5053138163 @default.
- W2603035054 hasAuthorship W2603035054A5067235730 @default.
- W2603035054 hasAuthorship W2603035054A5070331492 @default.
- W2603035054 hasAuthorship W2603035054A5078936080 @default.
- W2603035054 hasAuthorship W2603035054A5080445374 @default.
- W2603035054 hasConcept C121608353 @default.
- W2603035054 hasConcept C126322002 @default.
- W2603035054 hasConcept C141071460 @default.
- W2603035054 hasConcept C143998085 @default.
- W2603035054 hasConcept C146357865 @default.
- W2603035054 hasConcept C151730666 @default.
- W2603035054 hasConcept C2777863537 @default.
- W2603035054 hasConcept C2777982462 @default.
- W2603035054 hasConcept C2778260052 @default.
- W2603035054 hasConcept C2780962732 @default.
- W2603035054 hasConcept C50382708 @default.
- W2603035054 hasConcept C526805850 @default.
- W2603035054 hasConcept C66339696 @default.
- W2603035054 hasConcept C71924100 @default.
- W2603035054 hasConcept C86803240 @default.
- W2603035054 hasConcept C90924648 @default.
- W2603035054 hasConceptScore W2603035054C121608353 @default.
- W2603035054 hasConceptScore W2603035054C126322002 @default.
- W2603035054 hasConceptScore W2603035054C141071460 @default.
- W2603035054 hasConceptScore W2603035054C143998085 @default.
- W2603035054 hasConceptScore W2603035054C146357865 @default.
- W2603035054 hasConceptScore W2603035054C151730666 @default.
- W2603035054 hasConceptScore W2603035054C2777863537 @default.
- W2603035054 hasConceptScore W2603035054C2777982462 @default.
- W2603035054 hasConceptScore W2603035054C2778260052 @default.
- W2603035054 hasConceptScore W2603035054C2780962732 @default.
- W2603035054 hasConceptScore W2603035054C50382708 @default.
- W2603035054 hasConceptScore W2603035054C526805850 @default.
- W2603035054 hasConceptScore W2603035054C66339696 @default.
- W2603035054 hasConceptScore W2603035054C71924100 @default.
- W2603035054 hasConceptScore W2603035054C86803240 @default.
- W2603035054 hasConceptScore W2603035054C90924648 @default.
- W2603035054 hasLocation W26030350541 @default.
- W2603035054 hasOpenAccess W2603035054 @default.
- W2603035054 hasPrimaryLocation W26030350541 @default.
- W2603035054 isParatext "false" @default.
- W2603035054 isRetracted "false" @default.
- W2603035054 magId "2603035054" @default.
- W2603035054 workType "article" @default.